Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Hansa Biopharma AB
AB
Active
Org 5567345359
Scheelevägen 22, 223 63
Lund
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2007 · 19 years old
143 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Hansa Biopharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
213M
160M
106M
53M
0M
2020: 6M
6M
2020
2021: 34M (+467% vs 2020)
34M
+467%
2021
2022: 155M (+356% vs 2021)
155M
+356%
2022
2023: 134M (-14% vs 2022)
134M
-14%
2023
2024: 171M (+28% vs 2023)
171M
+28%
2024
EBITDA
SEK millions
0B
-0.3B
-0.5B
-0.8B
-1.1B
2020: -0.4B
-0.4B
2020
2021: -0.5B (-29% vs 2020)
-0.5B
-29%
2021
2022: -0.6B (-5% vs 2021)
-0.6B
-5%
2022
2023: -0.8B (-47% vs 2022)
-0.8B
-47%
2023
2024: -0.8B (+10% vs 2023)
-0.8B
+10%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
171 316
134 094
154 525
33 878
6 098
Staff expenses
—
—
—
—
—
EBITDA
−759 453
−846 969
−574 747
−547 947
−423 507
Depreciation & amort.
—
—
—
—
—
EBIT
−759 453
−846 969
−574 747
−547 947
−423 507
Net financials
−353 480
−42 338
−26 357
−2 369
1 557
Profit before tax
−925 769
−889 307
−596 131
−549 098
−421 644
Tax
−607
293 771
−604
−0
−0
Net profit
−926 376
−595 536
−596 735
−549 098
−421 644
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
2 062 596
2 399 675
1 699 620
1 011 270
1 433 094
Equity
674 449
1 216 945
618 389
755 948
1 241 578
Long-term debt
1 134 620
864 562
819 376
76 233
63 319
Short-term debt
253 527
318 168
264 445
171 732
113 771
Total debt
1 388 147
1 182 730
1 083 821
247 965
177 090
Financial ratios
5-year trend
EBITDA margin
−443,3 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
32,7 %
This company
38,2 %
Market median
This company
Market median
14% below market
2020
2024
Return on equity
−137,4 %
This company
18,4 %
Market median
This company
Market median
847% below market
2020
2024
Net profit margin
−540,7 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,08×
This company
1,12×
Market median
This company
Market median
93% below market
2020
2024
Debt / equity
2,06×
This company
0,62×
Market median
This company
Market median
232% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Hansa Biopharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
